Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EPIX

Essa Pharma Inc

Dec 08 • 04:00PM ET

5.46

Dollar change -0.03
Percentage change -0.55	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	4.22%	Shs Outstand	44.07M	Perf Week	1.30%
Market Cap	113.79M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	12.79%	Shs Float	19.96M	Perf Month	7.27%
Income	-27.42M	PEG	-	EPS next Q	-0.22	Inst Own	-	Short Float / Ratio	6.93% / 7.48	Perf Quarter	93.96%
Sales	0.00M	P/S	-	EPS this Y	13.25%	Inst Trans	-11.55%	Short Interest	1.38M	Perf Half Y	69.04%
Book/sh	3.41	P/B	1.60	EPS next Y	-52.74%	ROA	-16.66%	Target Price	19.40	Perf Year	63.47%
Cash/sh	7.32	P/C	0.75	EPS next 5Y	-	ROE	-17.05%	52W Range	2.29 - 6.40	Perf YTD	116.67%
Dividend	-	P/FCF	-	EPS past 5Y	58.12%	ROI	-18.25%	52W High	-14.69%	Beta	1.88
Dividend %	-	Quick Ratio	44.98	Sales past 5Y	0.00%	Gross Margin	-	52W Low	138.43%	ATR	0.48
Employees	-	Current Ratio	44.98	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	55.90	Volatility	8.66% 9.20%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	17.37%	Profit Margin	-	Rel Volume	0.18	Prev Close	5.49
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 08 BMO	Payout	-	Avg Volume	184.95K	Price	5.46
Recom	1.00	SMA20	2.73%	SMA50	22.54%	SMA200	65.09%	Volume	34,117	Change	-0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-23	Resumed	Oppenheimer	Outperform	$17
Mar-04-21	Initiated	Piper Sandler	Overweight	$50
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$10 → $17
Nov-02-20	Initiated	Jefferies	Buy	$17
Oct-25-19	Initiated	Oppenheimer	Outperform	$8

Nov-23-23 11:05AM	Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 Shares (GuruFocus.com)
Nov-21-23 08:00AM	ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +7.59%
Nov-08-23 08:00AM	ESSA Pharma to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-06-23 05:51PM	ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement (PR Newswire) -13.17%
Oct-30-23 10:59AM	EPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat (Zacks) +8.82%
05:41PM	Loading…
Oct-26-23 05:41PM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Oct-21-23 09:00AM	ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress (PR Newswire)
Sep-18-23 07:00AM	ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Aug-31-23 07:00AM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire)
Aug-14-23 08:43AM	EPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23 (Zacks) +6.57%
Aug-08-23 07:17AM	ESSA Pharma: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 (PR Newswire)
Jun-06-23 07:00AM	ESSA Pharma Appoints Lauren Merendino to its Board of Directors (PR Newswire)
Jun-01-23 07:00AM	ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (PR Newswire)
May-24-23 11:04AM	We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely (Simply Wall St.)
06:25AM	Loading…
May-18-23 06:25AM	EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research)
May-11-23 07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (PR Newswire) +6.43%
May-09-23 07:19AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (AP Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (PR Newswire)
Apr-18-23 07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-12-23 07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (PR Newswire) -5.82%
Mar-08-23 07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-07-23 05:19AM	ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Feb-23-23 05:43AM	EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research)
Feb-13-23 05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (PR Newswire) +5.15%
Feb-07-23 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (PR Newswire)
Feb-02-23 04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (PR Newswire) +6.52%
Jan-25-23 05:39AM	A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX) (Simply Wall St.) -5.50%
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Dec-21-22 05:07PM	Examining Penny Stocks with Technical Analysis (Investopedia) -5.91%
08:11AM	Loading…
Dec-19-22 08:11AM	EPIX: Advancing Multiple Clinical Trials in 2023 (Zacks Small Cap Research)
Dec-15-22 08:30AM	We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate (Simply Wall St.) -5.02%
Dec-13-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 (PR Newswire)
Nov-14-22 09:25AM	EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research) -7.90%
Nov-10-22 07:00AM	ESSA Pharma to Participate in Two Upcoming Investor Conferences (PR Newswire) +7.17%
Oct-31-22 11:13AM	ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials (Benzinga) -18.37%
08:58AM	J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment (MarketWatch)
07:00AM	ESSA Provides an Update on its Clinical Collaboration with Janssen (PR Newswire)
Oct-26-22 04:01PM	ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium (PR Newswire) +180.23%
07:00AM	Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Sep-13-22 07:00AM	ESSA Pharma Appoints Philip Kantoff to its Board of Directors (PR Newswire)
Aug-10-22 06:40AM	EPIX: Multiple Ongoing Studies of EPI-7386 (Zacks Small Cap Research)
Aug-04-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 (PR Newswire)
Jul-11-22 07:23AM	EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386 (Zacks Small Cap Research)
Jun-30-22 06:21PM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire) -9.48%
Jun-28-22 06:29AM	ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer (Benzinga) -9.55%
Jun-27-22 04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (PR Newswire)
Jun-02-22 07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (PR Newswire) +5.64%
May-27-22 08:12AM	EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22 (Zacks Small Cap Research)
May-10-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (PR Newswire) +7.68%
Apr-26-22 04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
Apr-25-22 10:20AM	EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR (Zacks Small Cap Research)
Apr-08-22 01:00PM	ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders (PR Newswire)
Mar-10-22 04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (PR Newswire)
Mar-09-22 11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
Mar-08-22 04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-04-22 05:16AM	EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research) +5.13%
Feb-03-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (PR Newswire)
Jan-19-22 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) -6.80%
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Nov-22-21 09:20AM	EPIX: Combination Studies Set to Initiate (Zacks Small Cap Research)
Nov-18-21 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 (PR Newswire)
Nov-08-21 07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences (PR Newswire)
Oct-28-21 04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
Oct-19-21 01:21PM	Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX) (Insider Monkey) +5.13%
Oct-07-21 10:25AM	ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact (Benzinga) +5.03%
09:00AM	ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 (PR Newswire)
06:30AM	Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration (PR Newswire)
Aug-31-21 04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences (PR Newswire)
Aug-24-21 06:30AM	EPIX: Unwarranted Selloff Following Phase 1 Trial Update (Zacks Small Cap Research) +6.93%
Aug-16-21 02:32PM	Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet (Benzinga) -34.48%
12:13PM	Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump (Benzinga)
10:22AM	Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August (Benzinga)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (PR Newswire)
Jul-13-21 12:38PM	Hedge Funds Are Crazy About ESSA Pharma Inc. (EPIX) (Insider Monkey)
May-25-21 07:00AM	ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference (PR Newswire)
May-10-21 10:59AM	EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen (Zacks Small Cap Research)
May-06-21 07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 (PR Newswire)

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERGER FRANKLIN M	Director	Nov 21	Buy	5.73	23,259	133,274	784,404	Nov 22 06:22 PM
BERGER FRANKLIN M	Director	Nov 03	Buy	5.99	16,471	98,661	760,875	Nov 16 05:45 PM
BERGER FRANKLIN M	Director	Nov 02	Buy	5.35	60,000	321,000	744,404	Nov 16 05:45 PM
Wood David S.	Chief Financial Officer	Dec 30	Buy	2.60	8,302	21,585	33,343	Jan 05 03:07 PM
Parkinson David Ross	Chief Executive Officer	Dec 30	Buy	2.60	3,067	7,974	56,542	Jan 05 06:18 PM
Parkinson David Ross	Chief Executive Officer	Dec 22	Buy	2.39	21,367	51,067	53,475	Jan 05 06:18 PM
BERGER FRANKLIN M	Director	Dec 21	Sale	2.41	72,223	174,401	684,404	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 20	Sale	2.53	43,617	110,351	756,627	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 16	Sale	2.67	50,000	133,500	800,244	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 15	Sale	2.88	82,000	235,800	850,244	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 14	Sale	3.00	25,000	75,000	932,244	Jan 05 03:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EPIX

Essa Pharma Inc

Upgrade your FINVIZ experience